Researchers Design Promising Cancer Drug(Ascenta Therapeutics Inc. which helped f...),Health
Navigation Links
Researchers Design Promising Cancer Drug
Date:3/7/2008
Ascenta Therapeutics Inc., which helped fund the study. Wang is a scientific founder of Ascenta, serves as its chief scientific adviser, and is the principal investigator on a research contract from Ascenta to U-M.
More information
The National Cancer Institute has more about cancer.
-- Robert Preidt
SOURCE: University of Michigan, news release, March 3, 2008
'/>"/>
| Copyright©2008 ScoutNews,LLC. All rights reserved |
Related medicine news :
1. Case Western Reserve University researchers identify colorectal cancer gene
2. On a roll: MIT researchers devise new cell-sorting system
3. Einstein researchers genetically engineer immune cells into potent weapons for battling HIV
4. Researchers control growth rate of replacement blood vessels, tissues
5. New protein discovery helps researchers understand autoimmune diseases
6. UF researchers warn parents about dangers of childhood foot burns
7. UCLA researchers find blood stem cells originate and are nurtured in the placenta
8. UCSF researchers validate new model for breast cancer risk assessment in multiple ethnic groups
9. Einstein researchers discover gene mutations linked to longer lifespans
10. U-M researchers ID promising new cancer drug
11. Researchers identify new genetic marker for breast cancer
Post Your Comments:
Related Image:
 Researchers Design Promising Cancer Drug |
(Date:11/21/2008)...holders to be held on January 8, 2009 , , T... International Inc. ("MedEmerg") (OTCBB: MDER), on..., announced today that it has obtained an interim ...oncerning its previously announced plan of arrange...lth Group Inc. ("AIM") will acquire all of MedEmer...
(Date:11/21/2008)...he University of Texas Health Science Center at Ho...ce in Aging Studies (TEXAS), to promote geriatrics...million award from the Donald W. Reynolds Foundati...ll allow us to teach geriatric medicine principles...to practicing physicians. With the reach of Lyndon...
(Date:11/21/2008)... Heska Corporation,(Nas...he New York Society of,Security Analysts, 12th An...ecember 2, 2008 at 1177 Avenue of the Americas, 2n...duled to begin at 9:35 a.m. Eastern Time (7:35 a.m...ebcast and for two weeks,following the presentati...
(Date:11/21/2008)... The Generic,Pharmaceut...tement today from,GPhA President and CEO Kathleen...TC) roundtable on "Emerging Health Care Competitio...at the FTC is conducting this roundtable demonstra...sumers have access to safe and,affordable biogene...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:GPhA Statement on FTC Roundtable on Biogenerics 2[0] Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc.[0] UT Houston launches geriatric training with $3.25 million in grant, matching funds[0] Heska to Present at New York Society of Security Analysts' 12th Annual Biotech and Specialty Pharma Conference[0] GPhA Statement on FTC Roundtable on Biogenerics
...A new study suggests that children with hemophilia...ses joint pain and swelling, are more at risk // ... their later years. But there is hope in preventi...dren, say researchers. Hemophiliac children are no...
...Eighty percent of the time childhood acute lymphob...bad news is doctors are not sure // why it doesn’...new research finds it could be because of a small ...rugs used to treat the disease. Researchers teste...
...A new study finds MRIs are significantly better at...ping cancers than standard mammograms // or clinic...omen with a lifetime breast cancer risk of 15 perc...so carried one of the genes known to put women at ...
...Moms-to-be have one more good reason not to smoke....ing during the early months // of pregnancy increa...e study, involved women from Scotland and England ...ere about six months old. Researchers asked about ...
Other Medicine News:(Date:11/20/2008)... WASHINGTON, Nov. 20 T...h & Gender Equity: , , WHAT: World AI... , Tuesday, November 25, 2008 , 11:00 a.m. E...trongly encouraged: https://cc.readytalk.com/r/1x...ions outpacing the number of people newly put on t...
(Date:11/20/2008)... , , , , PHILADELPHIA, Nov. 20 /P...K ) today announced that the United States Food an...proval for PROMACTA(R) (eltrombopag) for the treat...immune (idiopathic) thrombocytopenic purpura (ITP)...teroids, immunoglobulins or splenectomy. The appro...
(Date:11/20/2008)... REINACH, Switzerland, November 20 /PRNewswir...y that the Anti-infective Drugs Advisory Committee...as voted 17 to 2 against the,approval of intraven...nt for,the treatment of patients with complicated...luding those caused by methicillin-resistant Staph...
(Date:11/20/2008)... EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCal...he company will present results from the Phase 1B,...dvanced metastatic breast,cancer, BZL101, at the ...onal,Conference in Atlanta, Georgia. The Company...g abstract and will be presented as a part of the ...
Breaking Medicine Technology:Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Minnesota Reaches Milestone in Goal to End Homelessness 28155 1Minnesota Reaches Milestone in Goal to End Homelessness 28155 2NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders 28151 1NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders 28151 2NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders 28151 3Men are better at detecting infidelities 5647 1Men are better at detecting infidelities 5647 2Women at Higher Risk for Pulmonary Hypertension 28144 1Women at Higher Risk for Pulmonary Hypertension 28144 2[0] Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts[0] FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder[0] Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome[0] Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
...FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Ne...blication in the June 23 issue,of the journal The ...e therapy trial for Parkinson,s disease and the fi...s own brain cells for any adult,neurodegenerative ...in 12 patients with,advanced Parkinson,s disease d...
..."Electroloading of mature dendritic cells with tum...ponse", GAITHERSBURG, Md., and YOKOHAMA, Japan, Ju...net Co., Ltd. announce a,joint poster presentation...ociety for Cellular Therapy. The meeting is being,...presentation is entitled "Electroloading of mature...
Other Medicine Technology:Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 4Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 5Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 6MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,Australia 2MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,Australia 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's DiseaseMaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,Australia
This is adapted to microplate or card.
ScanGel® Incubator
The ID-Micro Typing System™ (ID-MTS) Gel Test is suitable for a broad range of blood bank applications. Applications that include antibody screening and identification, ABO blood grouping and R
...Mini-Vertical Gel System simplifies the process of...AGE format. It is able to run four gels at a time,...tility and throughput, the 120 mini-vertical runs ...120 mini-vertical has a modular design. The basic ...
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |